Do analysts rate OMCL or MDRX?

Omnicell presently has a consensus price target of $59.86, indicating a potential upside of 33.25%. Given Omnicell's stronger consensus rating and higher possible upside, analysts plainly believe Omnicell is more favorable than Veradigm. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Omnicell 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, OMCL or MDRX?

Omnicell has higher earnings, but lower revenue than Veradigm. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omnicell $1.18B 1.72 $2.05M $0.44 102.09 Veradigm $1.53B 0.40 N/A N/A N/A

Is OMCL or MDRX more profitable?

Omnicell has a net margin of 1.67% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 4.00% beat Veradigm's return on equity. Company Net Margins Return on Equity Return on Assets Omnicell 1.67% 4.00% 2.46% Veradigm N/A N/A N/A

Do analysts rate HSTM or MDRX?

HealthStream presently has a consensus price target of $24.00, indicating a potential downside of 14.53%. Given HealthStream's stronger consensus rating and higher probable upside, equities research analysts plainly believe HealthStream is more favorable than Veradigm. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HealthStream 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, HSTM or MDRX?

HealthStream has higher earnings, but lower revenue than Veradigm. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HealthStream $304.06M 2.70 $18.34M $0.67 41.91 Veradigm $1.53B 0.40 N/A N/A N/A

Which has higher earnings and valuation, CNGL or MDRX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Canna-Global Acquisition N/A N/A N/A N/A N/A Veradigm $1.53B 0.40 N/A N/A N/A

Is CNGL or MDRX more profitable?

Company Net Margins Return on Equity Return on Assets Canna-Global Acquisition N/A N/A N/A Veradigm N/A N/A N/A

Do analysts recommend MDRX or FUSE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Fusemachines 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, MDRX or FUSE?

Veradigm has higher revenue and earnings than Fusemachines. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradigm $1.53B 0.40 N/A N/A N/A Fusemachines $7.71M 3.72 -$930K -$0.03 N/A

Is MDRX or FUSE more profitable?

Company Net Margins Return on Equity Return on Assets Veradigm N/A N/A N/A Fusemachines N/A N/A N/A

Which has higher valuation and earnings, MDRX or OMQS?

Veradigm has higher revenue and earnings than OMNIQ. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradigm $1.53B 0.40 N/A N/A N/A OMNIQ $81.19M 0.02 -$29.43M $0.11 1.14

Is MDRX or OMQS more profitable?

Veradigm has a net margin of 0.00% compared to OMNIQ's net margin of -34.33%. Company Net Margins Return on Equity Return on Assets Veradigm N/A N/A N/A OMNIQ -34.33% N/A -61.97%

Veradigm (MDRX) Competitors

$5.05 +0.30 (+6.32%)

As of 07/10/2026 03:53 PM Eastern

Compare

MDRX vs. OMCL, HSTM, CNGL, FUSE, and OMQS

Should you buy Veradigm stock or one of its competitors? MarketBeat compares Veradigm with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Veradigm include Omnicell (OMCL), HealthStream (HSTM), Canna-Global Acquisition (CNGL), Fusemachines (FUSE), and OMNIQ (OMQS).

How does Veradigm compare to Omnicell?

Omnicell (NASDAQ:OMCL) and Veradigm (NASDAQ:MDRX) are both health care technology companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

Omnicell has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, Veradigm has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

97.7% of Omnicell shares are owned by institutional investors. 2.9% of Omnicell shares are owned by company insiders. Comparatively, 2.3% of Veradigm shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Omnicell has a net margin of 1.67% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 4.00% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	1.67%	4.00%	2.46%
Veradigm	N/A	N/A	N/A

In the previous week, Omnicell had 5 more articles in the media than Veradigm. MarketBeat recorded 5 mentions for Omnicell and 0 mentions for Veradigm. Omnicell's average media sentiment score of 0.42 beat Veradigm's score of 0.00 indicating that Omnicell is being referred to more favorably in the media.

Company	Overall Sentiment
Omnicell	Neutral
Veradigm	Neutral

Omnicell presently has a consensus price target of $59.86, indicating a potential upside of 33.25%. Given Omnicell's stronger consensus rating and higher possible upside, analysts plainly believe Omnicell is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Omnicell has higher earnings, but lower revenue than Veradigm.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.18B	1.72	$2.05M	$0.44	102.09
Veradigm	$1.53B	0.40	N/A	N/A	N/A

Summary

Omnicell beats Veradigm on 13 of the 14 factors compared between the two stocks.

How does Veradigm compare to HealthStream?

HealthStream (NASDAQ:HSTM) and Veradigm (NASDAQ:MDRX) are both small-cap health care technology companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

HealthStream has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market. Comparatively, Veradigm has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

69.6% of HealthStream shares are owned by institutional investors. 20.4% of HealthStream shares are owned by insiders. Comparatively, 2.3% of Veradigm shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

HealthStream has a net margin of 6.39% compared to Veradigm's net margin of 0.00%. HealthStream's return on equity of 6.47% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HealthStream	6.39%	6.47%	4.44%
Veradigm	N/A	N/A	N/A

HealthStream presently has a consensus price target of $24.00, indicating a potential downside of 14.53%. Given HealthStream's stronger consensus rating and higher probable upside, equities research analysts plainly believe HealthStream is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HealthStream	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, HealthStream had 4 more articles in the media than Veradigm. MarketBeat recorded 4 mentions for HealthStream and 0 mentions for Veradigm. HealthStream's average media sentiment score of 0.80 beat Veradigm's score of 0.00 indicating that HealthStream is being referred to more favorably in the media.

Company	Overall Sentiment
HealthStream	Positive
Veradigm	Neutral

HealthStream has higher earnings, but lower revenue than Veradigm.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HealthStream	$304.06M	2.70	$18.34M	$0.67	41.91
Veradigm	$1.53B	0.40	N/A	N/A	N/A

Summary

HealthStream beats Veradigm on 11 of the 13 factors compared between the two stocks.

How does Veradigm compare to Canna-Global Acquisition?

Canna-Global Acquisition (NASDAQ:CNGL) and Veradigm (NASDAQ:MDRX) are both small-cap business services companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

19.5% of Canna-Global Acquisition shares are held by institutional investors. 72.1% of Canna-Global Acquisition shares are held by insiders. Comparatively, 2.3% of Veradigm shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Canna-Global Acquisition	N/A	N/A	N/A
Veradigm	N/A	N/A	N/A

In the previous week, Canna-Global Acquisition's average media sentiment score of 0.00 equaled Veradigm'saverage media sentiment score.

Company	Overall Sentiment
Canna-Global Acquisition	Neutral
Veradigm	Neutral

Canna-Global Acquisition has a beta of -0.03, meaning that its stock price is 103% less volatile than the broader market. Comparatively, Veradigm has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canna-Global Acquisition	N/A	N/A	N/A	N/A	N/A
Veradigm	$1.53B	0.40	N/A	N/A	N/A

Summary

Canna-Global Acquisition and Veradigm tied by winning 2 of the 4 factors compared between the two stocks.

How does Veradigm compare to Fusemachines?

Veradigm (NASDAQ:MDRX) and Fusemachines (NASDAQ:FUSE) are both small-cap computer integrated systems design industry companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Fusemachines	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Fusemachines had 6 more articles in the media than Veradigm. MarketBeat recorded 6 mentions for Fusemachines and 0 mentions for Veradigm. Fusemachines' average media sentiment score of 0.95 beat Veradigm's score of 0.00 indicating that Fusemachines is being referred to more favorably in the news media.

Company	Overall Sentiment
Veradigm	Neutral
Fusemachines	Positive

Company	Net Margins	Return on Equity	Return on Assets
Veradigm	N/A	N/A	N/A
Fusemachines	N/A	N/A	N/A

Veradigm has higher revenue and earnings than Fusemachines.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradigm	$1.53B	0.40	N/A	N/A	N/A
Fusemachines	$7.71M	3.72	-$930K	-$0.03	N/A

46.8% of Fusemachines shares are held by institutional investors. 2.3% of Veradigm shares are held by insiders. Comparatively, 31.8% of Fusemachines shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Veradigm has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market. Comparatively, Fusemachines has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

Summary

Fusemachines beats Veradigm on 7 of the 9 factors compared between the two stocks.

How does Veradigm compare to OMNIQ?

Veradigm (NASDAQ:MDRX) and OMNIQ (NASDAQ:OMQS) are both small-cap computer integrated systems design industry companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

5.7% of OMNIQ shares are held by institutional investors. 2.3% of Veradigm shares are held by company insiders. Comparatively, 11.6% of OMNIQ shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Veradigm's average media sentiment score of 0.00 equaled OMNIQ'saverage media sentiment score.

Company	Overall Sentiment
Veradigm	Neutral
OMNIQ	Neutral

Veradigm has a net margin of 0.00% compared to OMNIQ's net margin of -34.33%.

Company	Net Margins	Return on Equity	Return on Assets
Veradigm	N/A	N/A	N/A
OMNIQ	-34.33%	N/A	-61.97%

Veradigm has higher revenue and earnings than OMNIQ.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradigm	$1.53B	0.40	N/A	N/A	N/A
OMNIQ	$81.19M	0.02	-$29.43M	$0.11	1.14

Veradigm has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, OMNIQ has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market.

Summary

Veradigm beats OMNIQ on 5 of the 8 factors compared between the two stocks.

Get Veradigm News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDRX vs. The Competition

Export

Metric	Veradigm	Computer integrated systems design Industry	Business Sector	NASDAQ Exchange
Market Cap	$617.62M	$3.09B	$6.91B	$12.66B
Dividend Yield	N/A	3.99%	3.12%	8.00%
P/E Ratio	23.25	2.11	29.27	24.53
Price / Sales	0.40	270.10	347.52	96.17
Price / Cash	N/A	N/A	23.47	60.03
Price / Book	N/A	N/A	5.74	6.38
Net Income	N/A	-$15.18M	$204.80M	$331.87M
7 Day Performance	-0.88%	-4.49%	-1.41%	0.37%
1 Month Performance	5.21%	3.01%	1.46%	0.59%
1 Year Performance	N/A	-12.33%	16.36%	22.26%

Veradigm Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDRX Veradigm	N/A	$5.05 +6.3%	N/A	+0.0%	$617.62M	$1.53B	23.25	8,000	Gap Up
OMCL Omnicell	3.6414 of 5 stars	$40.67 -0.6%	$59.86 +47.2%	+56.6%	$1.85B	$1.23B	92.42	3,580	Analyst Downgrade
HSTM HealthStream	2.4119 of 5 stars	$27.32 +0.7%	$24.00 -12.2%	+5.6%	$797.85M	$304.06M	40.75	1,160	Insider Trade
CNGL Canna-Global Acquisition	N/A	$9.00 flat	N/A	N/A	$59.49M	N/A	N/A	2
FUSE Fusemachines	0.6154 of 5 stars	$1.09 +4.3%	N/A	N/A	$31.40M	$7.64M	N/A	317

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDRX) was last updated on 7/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veradigm (MDRX) Competitors

MDRX vs. OMCL, HSTM, CNGL, FUSE, and OMQS

How does Veradigm compare to Omnicell?

Summary

How does Veradigm compare to HealthStream?

Summary

How does Veradigm compare to Canna-Global Acquisition?

Summary

How does Veradigm compare to Fusemachines?

Summary

How does Veradigm compare to OMNIQ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDRX vs. The Competition

Veradigm Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Veradigm (MDRX) Competitors

MDRX vs. OMCL, HSTM, CNGL, FUSE, and OMQS

How does Veradigm compare to Omnicell?

Which has more volatility & risk, OMCL or MDRX?

Do institutionals and insiders believe in OMCL or MDRX?

Is OMCL or MDRX more profitable?

Does the media refer more to OMCL or MDRX?

Do analysts rate OMCL or MDRX?

Which has preferable valuation and earnings, OMCL or MDRX?

Summary

How does Veradigm compare to HealthStream?

Which has more risk & volatility, HSTM or MDRX?

Do insiders & institutionals believe in HSTM or MDRX?

Is HSTM or MDRX more profitable?

Do analysts rate HSTM or MDRX?

Does the media prefer HSTM or MDRX?

Which has higher valuation & earnings, HSTM or MDRX?

Summary

How does Veradigm compare to Canna-Global Acquisition?

Do institutionals and insiders have more ownership in CNGL or MDRX?

Is CNGL or MDRX more profitable?

Does the media favor CNGL or MDRX?

Which has more volatility & risk, CNGL or MDRX?

Which has higher earnings and valuation, CNGL or MDRX?

Summary

How does Veradigm compare to Fusemachines?

Do analysts recommend MDRX or FUSE?

Does the media prefer MDRX or FUSE?

Is MDRX or FUSE more profitable?

Which has preferable valuation and earnings, MDRX or FUSE?

Do insiders and institutionals believe in MDRX or FUSE?

Which has more risk & volatility, MDRX or FUSE?

Summary

How does Veradigm compare to OMNIQ?

Do institutionals and insiders believe in MDRX or OMQS?

Does the media refer more to MDRX or OMQS?

Is MDRX or OMQS more profitable?

Which has higher valuation and earnings, MDRX or OMQS?

Which has more volatility and risk, MDRX or OMQS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDRX vs. The Competition

Veradigm Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools